InvestorsHub Logo
Followers 105
Posts 4947
Boards Moderated 0
Alias Born 10/20/2015

Re: biosectinvestor post# 504756

Sunday, 08/14/2022 12:37:06 PM

Sunday, August 14, 2022 12:37:06 PM

Post# of 693073
That is right many have and many will. RA approval in not necessary to advance from Market caps in hundreds of millions to multi billions. The element that causes the stratospheric upward valuations is "market recognition" of the potential. For instance Arrowhead Pharma rose from $200 million Market Cap to $7 Billion Market Cap in 18 months(35x) before any drug approval. Look at ARWR 20 year chart. What caused the "Market" to finally grasp ARWR potential was likely the JNJ partnership. Anavex Life Sciences rose from a share price of $1.26 to a spike of over $30 in 18 months. On no drug approval or even partnership. Likely the "Market Recognition" for AVXL came because how the Market was revaluing Cassava another company targeting ALZ.
Look at the 20 year chart of AVXL.
NWBO in its current depressed valuation is like sweating dynamite any little shock from positive news could cause it to explode upwards. Look at the 20 year chart of NWBO. Then view again the 20 year charts of ARWR and AVXL. If one wonders if Cancer Companies have the potential of 25x revaluation on market recognition in just a few months then try to find a 2017 chart of Celator CPXX.
Make no mistake, NWBO at its current valuation is like wet dynamite. I do not know when and what what will cause it to explode just that likely it will explode and it might not take a big catalyst to set it off. The Market will not wait for approval to revalue NWBO I can nearly guarantee that much.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NWBO News